A Phase I study examining the feasibility of intermittent convection-enhanced delivery (CED) of MTX110 for the treatment of children with newly diagnosed diffuse midline gliomas

panobinostat (MTX110) - Biodexa Pharma

Farydak (panobinostat) - Secura Bio

https://virtual.oxfordabstracts.com/#/event/public/5131/submission/743

Luca Szalontay1; Travis CreveCoeur1; Justin Neira1; Zachary Englander1; Eleonora Spinazzi1; Peter Canoll1; James Garvin1; Jessica Fino1; Dmitry Zamoryakhin2; Alexis Maddocks1; Neil Feldstein1; Jeffrey Bruce1; Cheng-Chia Wu1; Stergios Zacharoulis1,3

Jul 2, 2024